Most people with frontotemporal dementia (FTD) live 7 to 13 years from the time symptoms first appear, though the specific subtype of FTD has a major influence on that range. Because FTD is frequently misdiagnosed early on, many people don’t receive a correct diagnosis for about four years after symptoms start, which means the remaining time after diagnosis is often shorter than the full disease course suggests.
Survival by FTD Subtype
FTD is not a single disease. It’s an umbrella term for several conditions that damage the frontal and temporal lobes of the brain, and each one follows a somewhat different timeline.
The behavioral variant (bvFTD) is the most common form, marked by personality changes, impulsive behavior, and emotional blunting. Median survival from symptom onset is roughly 8.7 to 10.5 years, depending on the study. The language-focused subtypes, grouped under primary progressive aphasia (PPA), vary more widely. Semantic dementia, which erodes the ability to understand words and recognize objects, tends to progress the slowest, with a median survival of about 12 years from onset. Progressive nonfluent aphasia (PNFA), where speech becomes halting and effortful, falls in a similar range to bvFTD at around 8.6 years. The logopenic variant, which affects word-finding and sentence repetition, carries the shortest median survival at roughly 7 years.
These are medians, not limits. Some people live well beyond these numbers, while others progress faster. But the subtype is one of the strongest predictors of how the disease will unfold.
When FTD Overlaps With Motor Neuron Disease
About 10 to 15 percent of people with FTD also develop amyotrophic lateral sclerosis (ALS), a condition that attacks the nerve cells controlling movement. This overlap dramatically shortens survival. The median drops to about three years and four months from symptom onset, compared to roughly 7.5 years for FTD alone. The combination accelerates decline on both fronts: cognitive and behavioral symptoms worsen faster, and the physical deterioration from ALS, particularly the loss of the ability to swallow and breathe, compounds the progression. If ALS symptoms appear alongside or shortly after an FTD diagnosis, the prognosis changes significantly.
How Genetic Mutations Affect the Timeline
Around 30 to 40 percent of FTD cases have a family history of the disease, and three gene mutations account for most inherited cases. Each one influences when symptoms start and how long the disease lasts.
People with MAPT mutations tend to develop symptoms earliest, at an average age of about 50, but they also have the longest disease course at roughly 9.3 years. Those with C9orf72 mutations, the most common genetic cause and the one linked to the FTD-ALS overlap, show symptoms around age 58 on average and survive about 6.4 years. GRN mutations produce the latest onset, around age 61, with a disease duration of about 7.1 years. For MAPT carriers in particular, the specific mutation and even which family they belong to explains a large share of the variation in outcomes, meaning that family history can be a useful guide.
The Diagnostic Delay Problem
One of the most frustrating aspects of FTD is how long it takes to get a correct diagnosis. A large meta-analysis found the average delay is 4.2 years from symptom onset to a final FTD diagnosis, longer than for most other types of dementia. Because early symptoms often look like depression, a midlife crisis, or a psychiatric condition, people frequently cycle through several wrong diagnoses first.
This matters for survival estimates. If someone is told they have FTD and asks how long they have, the answer depends on when symptoms actually started, not when the diagnosis was made. A person diagnosed “today” may already be four or five years into the disease. Studies measuring survival from diagnosis rather than from onset report shorter windows of roughly 6 to 8 years, but that’s largely because the clock started ticking years before anyone identified the real problem.
What Happens in the Final Stages
FTD progresses gradually, but the late stages bring a recognizable set of changes. Speech typically narrows to single words or phrases, and understanding of what others say becomes very limited. The person needs help with most daily activities, from dressing to eating. Mobility declines, and many people eventually become bed-bound. Swallowing difficulties become increasingly dangerous, and eating less is common. Bowel and bladder incontinence develops. Sleep increases while periods of wakefulness shorten.
In the final days, the decline accelerates. The person may lose consciousness, become unable to swallow at all, develop irregular breathing, or show a rattly chest sound. Hands and feet often turn cold. Some people become restless or agitated during this period.
What Most People Die From
FTD itself doesn’t directly cause death in the way a heart attack does. Instead, the severe brain degeneration leads to complications that become fatal. The single most common cause is aspiration pneumonia, responsible for about 40 percent of deaths in one study of bvFTD and young-onset Alzheimer’s patients. As the brain loses the ability to coordinate swallowing, food or liquid enters the lungs and causes infection. The second most common cause, accounting for roughly a third of deaths, is cachexia with dehydration, a state of extreme weight loss and wasting that develops when the person can no longer eat or drink enough to sustain their body. Recurring infections of other kinds make up most of the remaining cases.
Palliative Care and Quality of Life
No treatment currently slows or stops FTD’s progression, which makes the focus on quality of life especially important. Palliative care, introduced early, has been shown to improve symptom control, reduce pain, prevent unnecessarily aggressive medical interventions, and increase satisfaction for both the person with dementia and their family. It also helps caregivers feel more in control and reduces their own burden. For people with advanced FTD, hospice care specifically lowers the chance of hospitalization in the final month of life and increases the likelihood that daily pain is consistently treated.
Palliative care doesn’t change the underlying disease trajectory, but it meaningfully changes the experience of living with it. People who are referred earlier tend to benefit more, partly because there’s time to establish goals and preferences before communication becomes impossible.